Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05912387 · ClinicalTrials.gov registry record · Early Phase 1

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

A Early Phase 1 study of Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis, sponsored by Stanford University.

Recruiting
Registry status
Early Phase 1
Development phase
15
Enrollment target
1
Study location

NCT05912387: Recruiting Early Phase 1 study of Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis, sponsored by Stanford University.

NCT05912387 is a Early Phase 1 study of Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis that is actively recruiting participants, run by Stanford University. The registered enrollment target is 15 participants, below the 42,261-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05912387, a Early Phase 1 study of Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model

Primary Outcome

BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.

Interventions

  • DRUG Rosuvastatin

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-05-31
Est. Completion 2027-12-31
Phase Early Phase 1
Stanford University

1,744 total trials

What NCT05912387 shows while recruiting

NCT05912387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 42,261-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Inflammatory Bowel Diseases appearing as the primary indexed condition, and to 1 intervention - of which Rosuvastatin is the first listed.

NCT05912387 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05912387 about?

NCT05912387 is a clinical study titled "Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study". PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The invest...

What is the current status of trial NCT05912387?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2023-05-31. Estimated completion is 2027-12-31.

What conditions does trial NCT05912387 study?

This clinical trial studies the following conditions: Inflammatory Bowel Diseases, Primary Sclerosing Cholangitis.

What interventions are being tested in trial NCT05912387?

The interventions under investigation include: Rosuvastatin (DRUG).

Who is sponsoring clinical trial NCT05912387?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05912387 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammatory Bowel Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05912387's enrollment target sits among peer trials

15 46th of 48 higher than 1 of 48 other Inflammatory Bowel Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammatory Bowel Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05912387, the US trial registry maintained by the National Library of Medicine. NCT05912387 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.